The trials that tested stopping GLP-1 medication tested stopping it abruptly. We could not find a randomised trial that tested tapering the dose gradually, or compared a taper against an abrupt stop. That absence is the single most important fact about this topic, and it is almost never stated. This article covers what the withdrawal trials actually tested, what "lowest effective dose" means as a prescribing principle, and what can honestly be planned when the evidence for the method itself does not exist.
Lowest effective dose: the smallest dose that still achieves the clinical goal, rather than the highest dose a person can tolerate. A principle for how a medication is prescribed, not a number.
What the withdrawal trials actually tested
All of them tested the same thing: taking the medication away.
In STEP 4, participants completed a 20-week run-in on semaglutide and were then randomised either to continue or to switch to placebo. Those switched to placebo regained 6.9% of body weight over 48 weeks; those continuing lost a further 7.9% (Rubino 2021). SURMOUNT-4 used the same design with tirzepatide after a 36-week lead-in: 14.0% regained on placebo against a further 5.5% lost on continued treatment (Aronne 2024). The STEP 1 extension followed people after treatment ended and found about two-thirds of lost weight returned within a year (Wilding 2022).
A meta-analysis pooling eight of these trials confirms the pattern across the class (Berg 2025).
So the literature answers "what happens if the medication is removed" thoroughly, and says nothing at all about "what happens if the dose is reduced gradually".
Is tapering better than stopping abruptly?
Nobody knows. That is the honest answer, and it is worth stating plainly because a great deal of confident advice exists on this question with nothing behind it.
We searched the published literature for a trial testing this and did not find one. No randomised trial has compared a gradual dose reduction against an abrupt stop, or against continued treatment. Whether it is better to reduce the dose gradually, lengthen the interval between doses, or do something else entirely, is an open question.
What does exist is one retrospective cohort from a commercial digital clinic, in which tapering was offered as a clinician-guided personal choice rather than randomised. That cohort reported a mean weight loss of 16.7% at 64 weeks on individualised dosing (Seier 2025). It has no control group, the clinic that produced the data also sells the programme being evaluated, and it was not designed to test whether tapering prevents regain. It is worth knowing about. It is not evidence that tapering works.
What this clinic does, with the evidence in that state
Somebody still has to decide how a patient actually comes off, and "no trial has tested it" is not a plan. At GetLean, we favour a gradual reduction under a doctor's guidance rather than a cliff-edge stop, which allows your appetite to adjust incrementally.
That is a clinical position, not a finding, and the paragraphs above are the reason it cannot be stated as more than one. No trial has compared the two approaches, so this is a considered preference held by the doctors who practise here rather than something the literature settles. Your own schedule is set by your doctor, for you.
Then what does "lowest effective dose" mean?
It is a prescribing principle, and it applies while someone is on treatment rather than only at the end of it.
The principle is that the goal is the smallest dose that achieves the clinical objective, not the largest dose a person can tolerate. What that dose is differs between people, which is why it is a principle rather than a number — and why it is set by the prescribing doctor rather than by a rule.
Two things follow that are worth understanding.
It is a decision for the prescribing doctor, made with the individual in front of them. Dose changes depend on how someone has responded, what side effects they have had, what else they take and what the goal is. No article can supply that, and one that offered a schedule would be inventing it.
Reaching a lower dose is not the same as coming off. Continued treatment at some dose is the option with the strongest evidence behind it — in both randomised-withdrawal trials, the groups who kept taking the medication kept their results and the groups who stopped did not (Rubino 2021, Aronne 2024). Whether a reduced maintenance dose holds the same result has not been tested.
What can actually be planned
If the method of coming off has no evidence base, the thing to plan is what replaces the medication's effect.
This is where the evidence is much better. Resistance training combined with caloric restriction keeps lean mass statistically unchanged across 114 trials and 4,184 people (Lopez 2022). Muscle that is still there when the medication stops is muscle that carries on doing its job. Protein intake, an eating pattern that has become ordinary rather than effortful, and training that has become a habit are all things that do not stop when a prescription does.
At GetLean, our philosophy is that GLP-1 medication should act as a catalyst — not something to depend on indefinitely. The exit is worth thinking about from the beginning, because the things that make an exit survivable take months to establish and cannot be assembled in the final few weeks.
What we can say honestly: the weight returns when the medication is removed, the rate at which it returns varies enormously between people, and what someone has built in the meantime is the part that is still under their control.
Individual results vary, and clinical-trial figures describe the populations studied. Never change or stop a prescribed medication on your own — that is a conversation with the doctor who prescribed it.
Common questions
Is it better to taper off GLP-1 than stop suddenly?
Nobody knows, because it has not been tested. The withdrawal trials switched participants abruptly to placebo rather than tapering them (Berg 2025), so there is no comparison to draw on. It is a decision to make with your doctor. At GetLean, we favour a gradual reduction under a doctor's guidance rather than a cliff-edge stop, which allows your appetite to adjust incrementally.
What does lowest effective dose mean?
The smallest dose that still achieves the clinical goal, rather than the highest dose a person can tolerate. It is a prescribing principle rather than a number, and the dose that suits one patient will not suit another.
Will tapering stop the weight coming back?
There is no trial evidence either way. What the withdrawal trials show is that weight returns when the medication is removed (Wilding 2022); whether a gradual reduction changes that has not been studied.
Can you stay on a lower maintenance dose instead of stopping?
Continuing treatment is the option with the strongest evidence — in SURMOUNT-4 those continuing lost a further 5.5% while those switched to placebo regained 14.0% (Aronne 2024). Whether a reduced maintenance dose achieves the same result has not been tested, and it is a question for your doctor.
How long does it take to come off GLP-1 medication?
There is no established protocol, because no trial has tested one. The more useful thing to plan is not the schedule but what replaces the medication's effect — the training and eating pattern that continue afterwards.